Robin L Jones1,2, Johanna C Bendell3, David C Smith4, Konstanze Diefenbach5, John Lettieri6, Oliver Boix7, A Craig Lockhart8, Cindy O'Bryant9, Kathleen N Moore10. 1. Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA. rjones@seattlecca.org. 2. Sarcoma Unit, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK. rjones@seattlecca.org. 3. Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA. 4. Internal Medicine Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA. 5. Bayer Pharma AG, Berlin, Germany. 6. Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. 7. Bayer Pharma AG, Wuppertal, Germany. 8. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA. 9. Department of Clinical Pharmacy, University of Colorado Cancer Center, Aurora, CO, USA. 10. Stephenson Cancer Center, Oklahoma University HSC, Oklahoma City, OK, USA.
Abstract
PURPOSE: To characterize the cardiovascular safety profile of regorafenib in patients with advanced cancer. METHODS: Patients received regorafenib 160 mg/day for 21 days followed by a 7-day break. The primary endpoint was the change from baseline in QTcF at the regorafenib t(max) (Day 21, Cycle 1 or 2) and changes in left ventricular ejection fraction (LVEF) from baseline on Cycle 2, Day 21. Secondary objectives were pharmacokinetics, safety, anti-tumor activity and effects on electrocardiogram intervals. QT intervals were corrected using the methods of Fridericia (QTcF) and Bazett (QTcB). LVEF was assessed by multigated acquisition scanning. RESULTS:Fifty-three patients were enrolled, and all received at least one dose ofregorafenib 160 mg. Twenty-five patients received regorafenib for 21 days without dose reduction. The mean change from baseline in QTcF at t(max) was (-)2 ms (90 % CI -8, 3). No patient experienced a change from baseline in QTcF > 60 ms, and two had QTcF changes between 30 and 60 ms. No patient had a QTcF or QTcB > 480 ms. In 27 patients who received at least 80 mg of regorafenib, the mean change from baseline in LVEF% ± SD was 1.7 ± 7.8. In 14 patients without a dose reduction, the mean change from baseline in LVEF% was (-)0.1 ± 8.6 at Cycle 2, Day 21. Four patients experienced a LVEF decrease between 10 and 20 %. CONCLUSION: The effects of regorafenib on the QT/QTc interval and LVEF were modest and unlikely to be of clinical significance in the setting of advanced cancer therapy.
RCT Entities:
PURPOSE: To characterize the cardiovascular safety profile of regorafenib in patients with advanced cancer. METHODS:Patients received regorafenib 160 mg/day for 21 days followed by a 7-day break. The primary endpoint was the change from baseline in QTcF at the regorafenib t(max) (Day 21, Cycle 1 or 2) and changes in left ventricular ejection fraction (LVEF) from baseline on Cycle 2, Day 21. Secondary objectives were pharmacokinetics, safety, anti-tumor activity and effects on electrocardiogram intervals. QT intervals were corrected using the methods of Fridericia (QTcF) and Bazett (QTcB). LVEF was assessed by multigated acquisition scanning. RESULTS: Fifty-three patients were enrolled, and all received at least one dose of regorafenib 160 mg. Twenty-five patients received regorafenib for 21 days without dose reduction. The mean change from baseline in QTcF at t(max) was (-)2 ms (90 % CI -8, 3). No patient experienced a change from baseline in QTcF > 60 ms, and two had QTcF changes between 30 and 60 ms. No patient had a QTcF or QTcB > 480 ms. In 27 patients who received at least 80 mg of regorafenib, the mean change from baseline in LVEF% ± SD was 1.7 ± 7.8. In 14 patients without a dose reduction, the mean change from baseline in LVEF% was (-)0.1 ± 8.6 at Cycle 2, Day 21. Four patients experienced a LVEF decrease between 10 and 20 %. CONCLUSION: The effects of regorafenib on the QT/QTc interval and LVEF were modest and unlikely to be of clinical significance in the setting of advanced cancer therapy.